Hydrolysis of bimatoprost (Lumigan) to its free acid by ocular tissue in vitro
- PMID: 12648303
- DOI: 10.1089/108076803762718105
Hydrolysis of bimatoprost (Lumigan) to its free acid by ocular tissue in vitro
Abstract
We determined whether bimatoprost, which has been reported to act via putative prostamide receptors, could be hydrolyzed to its free acid (17-phenyl-PGF(2 alpha)), a potent FP receptor agonist, by human ocular tissue in vitro. We developed a gas chromatography/mass spectrometric method to measure 17-phenyl-PGF(2 alpha) levels at sub-picomolar levels. We then analyzed the amount of 17-phenyl-PGF(2 alpha) present after incubation of 50 microl Lumigan (0.03% bimatoprost) with eye tissue using this assay. We found that cornea, sclera, iris, and ciliary body, all rapidly hydrolyzed bimatoprost to 17-phenyl-PGF(2 alpha) with linear kinetics at a rate of 6.3, 2.0, 2.8, and 1.5 pmol mg tissue(-1) hr(-1), respectively. For cornea, sclera, and ciliary body, this linear rate of hydrolysis continued over a period of at least three hours, while iris-induced hydrolysis did not continue beyond one hour. Our findings suggest that bimatoprost can act as prodrug for FP receptor activation and questions the concept of a "prostamide receptor" agonist.
Similar articles
-
Prostamides (prostaglandin-ethanolamides) and their pharmacology.Br J Pharmacol. 2008 Feb;153(3):410-9. doi: 10.1038/sj.bjp.0707434. Epub 2007 Aug 27. Br J Pharmacol. 2008. PMID: 17721551 Free PMC article. Review.
-
The hydrolysis of the prostaglandin analog prodrug bimatoprost to 17-phenyl-trinor PGF2alpha by human and rabbit ocular tissue.J Ocul Pharmacol Ther. 2003 Apr;19(2):97-103. doi: 10.1089/108076803321637627. J Ocul Pharmacol Ther. 2003. PMID: 12804054
-
Comparison of prostaglandin F2alpha, bimatoprost (prostamide), and butaprost (EP2 agonist) on Cyr61 and connective tissue growth factor gene expression.J Biol Chem. 2003 Jul 18;278(29):27267-77. doi: 10.1074/jbc.M301009200. Epub 2003 Apr 30. J Biol Chem. 2003. PMID: 12724323
-
Comparison of human ocular distribution of bimatoprost and latanoprost.J Ocul Pharmacol Ther. 2012 Apr;28(2):134-45. doi: 10.1089/jop.2011.0097. Epub 2011 Dec 2. J Ocul Pharmacol Ther. 2012. PMID: 22136089 Clinical Trial.
-
The pharmacology of bimatoprost (Lumigan).Surv Ophthalmol. 2001 May;45 Suppl 4:S337-45. doi: 10.1016/s0039-6257(01)00224-7. Surv Ophthalmol. 2001. PMID: 11434936 Review.
Cited by
-
Levels of bimatoprost acid in the aqueous humour after bimatoprost treatment of patients with cataract.Br J Ophthalmol. 2007 May;91(5):629-32. doi: 10.1136/bjo.2006.110155. Epub 2006 Nov 29. Br J Ophthalmol. 2007. PMID: 17135335 Free PMC article. Clinical Trial.
-
Role of prostaglandins and specific place in therapy of bimatoprost in the treatment of elevated intraocular pressure and ocular hypertension: A closer look at the agonist properties of bimatoprost and the prostamides.Clin Ophthalmol. 2009;3:663-70. doi: 10.2147/opth.s6337. Epub 2009 Dec 29. Clin Ophthalmol. 2009. PMID: 20054414 Free PMC article.
-
Ocular Tolerability of Preservative-Free Tafluprost and Latanoprost: in vitro and in vivo Comparative Study.Open Ophthalmol J. 2016 May 31;10:146-53. doi: 10.2174/1874364101610010146. eCollection 2016. Open Ophthalmol J. 2016. PMID: 27347250 Free PMC article.
-
First-line treatment for elevated intraocular pressure (IOP) associated with open-angle glaucoma or ocular hypertension: focus on bimatoprost.Clin Ophthalmol. 2007 Sep;1(3):225-32. Clin Ophthalmol. 2007. PMID: 19668476 Free PMC article.
-
Prostamides (prostaglandin-ethanolamides) and their pharmacology.Br J Pharmacol. 2008 Feb;153(3):410-9. doi: 10.1038/sj.bjp.0707434. Epub 2007 Aug 27. Br J Pharmacol. 2008. PMID: 17721551 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical